Adjusted comparison of outcomes between patients from cartitude-1 versus multiple myeloma patients with prior exposure to pi, imid and anti-cd-38 from a german registry

Maximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, Mounzer Agha, Joris Diels, Francesca Ghilotti, Nolen J. Perualila, Jedelyn Cabrieto, Benjamin Haefliger, Henrik Sliwka, Jordan M. Schecter, Carolyn C. Jackson, Yunsi Olyslager, Muhammad Akram, Tonia Nesheiwat, Lenka Kellermann, Sundar Jagannath

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Ciltacabtagene autoleucel (cilta-cel) is a Chimeric antigen receptor T-cell therapy with the potential for long-term disease control in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM). As cilta-cel was assessed in the single-arm CARTITUDE-1 clinical trial, we used an external cohort of patients from the Therapie Monitor registry fulfilling the CARTITUDE-1 inclusion criteria to evaluate the effectiveness of cilta-cel for overall survival (OS) and time to next treatment (TTNT) vs. real-world clinical practice. Individual patient data allowed us to adjust the comparisons between both cohorts, using the inverse probability of treatment weighting (IPW; average treatment effect in the treated population (ATT) and overlap population (ATO) weights) and multivariable Cox proportional hazards regression. Outcomes were compared in intention-to-treat (HR, IPW-ATT: TTNT: 0.13 (95% CI: 0.07, 0.24); OS: 0.14 (95% CI: 0.07, 0.25); IPW-ATO: TTNT: 0.24 (95% CI: 0.12, 0.49); OS: 0.26 (95% CI: 0.13, 0.54)) and modified intention-to-treat (HR, IPW-ATT: TTNT: 0.24 (95% CI: 0.09, 0.67); OS: 0.26 (95% CI: 0.08, 0.84); IPW-ATO: TTNT: 0.26 (95% CI: 0.11, 0.59); OS: 0.31 (95% CI: 0.12, 0.79)) populations. All the comparisons were statistically significant in favor of cilta-cel. These results highlight cilta-cel’s potential as a novel, effective treatment to address unmet needs in patients with RRMM.

Original languageEnglish
Article number5996
JournalCancers
Volume13
Issue number23
DOIs
StatePublished - 1 Dec 2021

Keywords

  • Adjusted comparison
  • CAR-T
  • CARTITUDE-1
  • Chimeric antigen receptor T-cell therapy
  • Cilta-cel
  • Ciltacabtagene autoleucel
  • Indirect treatment comparison
  • Relapsed or refractory multiple myeloma

Fingerprint

Dive into the research topics of 'Adjusted comparison of outcomes between patients from cartitude-1 versus multiple myeloma patients with prior exposure to pi, imid and anti-cd-38 from a german registry'. Together they form a unique fingerprint.

Cite this